KALA News and Press, Kala Pharmaceuticals Inc. From 05/30/19

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will present at the Jefferies 2019 ...

Kala Pharmaceuticals, Inc. (KALA) Q1 2019 Earnings Conference Call May 9, 2019 8:00 AM ET Company Participants Mary Reumuth – Chief Financial Officer Mark Iwicki – Chairman, President and Chief Executive Officer Todd Bazemore – Chief Operating Officer Kim B...

Kala Pharmaceuticals (NASDAQ: KALA ): Q1 GAAP EPS of -$0.75 in-line. More news on: Kala Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

–Conference Call and Webcast Today at 8:00 a.m. ET– Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug ...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will present at the Bank of America...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will report first quarter 2019 fina...

Gainers: ATAI   +29.3% . MRTX   +3.1% . KALA   +3.1% . HPE   +2.4% . PKD   +2.1% . More news on: ATA Inc., Mirati Therapeutics, Inc., Kala Pharmaceuticals, Inc., Stocks on the move, Read more ...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will present at the H.C. Wainwright...

Kala Pharmaceuticals, Inc. (KALA) Q4 2018 Earnings Conference Call March 11, 2019 4:30 p.m. ET Company Participants Mary Reumuth - CFO Mark Iwicki - Chairman, President, CEO Kim Brazzell - Chief Medical Officer Todd Bazemore - COO Hongming Chen - Chief Scientific Officer C...

Kala Pharmaceuticals (NASDAQ: KALA ): Q4 GAAP EPS of -$0.76 misses by $0.24. More news on: Kala Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...